The FDA issued new guidance for sponsors of drugs designed to treat hay fever as well as other cold-like symptoms that aren’t caused by allergies. In a pair of final guidances, the agency urges drug sponsors to focus on real-world settings when trying to determine doses.
Simplifying Global Compliance
FDA Releases Final Guidance on Drugs for Hay Fever, Non-Allergic Rhinitis
International Pharmaceutical Regulatory Monitor
